Using special nanoparticles to improve drug delivery for aggressive brain tumors.
Fluorescent Indocarbocyanine PEGylated Lipid Nanoparticles for Understanding and Overcoming Barriers to Drug Delivery in Invasive Glioblastoma
This study is looking at a new way to help treat glioblastoma, a tough brain tumor, by using special tiny particles that can shine a light on and target the tumor cells, making it easier for doctors to deliver medicine right where it's needed.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10894669 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma, a highly aggressive brain tumor that is difficult to treat due to its ability to hide behind protective barriers in the brain. The study investigates how fluorescent indocarbocyanine lipids, formulated in PEGylated lipid nanoparticles, can effectively penetrate these barriers and target invasive tumor cells. By understanding the mechanisms of how these nanoparticles accumulate in tumors, the research aims to enhance drug delivery and improve treatment outcomes for patients. The approach includes studying the trafficking of these nanoparticles and their interaction with tumor cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma who are seeking innovative treatment options.
Not a fit: Patients with non-invasive brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially extending survival and improving quality of life for patients.
How similar studies have performed: Previous research has shown promise in using nanoparticles for drug delivery in cancer treatment, indicating potential success for this novel approach.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Simberg, Dmitri — University of Colorado Denver
- Study coordinator: Simberg, Dmitri
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.